Free Newsletter
Genzyme's Myozyme approved
An FDA panel of health experts voted to support approval for mass production of Genzyme's Myozyme for the treatment of Pompe disease, a rare muscle disorder that can lead to fatal respiratory problems. The FDA panel members ruled, 16-1, that the drug was effective, and most recommended accelerated approval of Myozyme, so long as Genzyme was diligent with follow-up. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: